MORE ON THIS TOPIC Layoff Tracker Stubborn Layoff Trend Continues Across Biopharma in 2024 December 23, 2024 · 207 min read · BioSpace Editorial Staff Drug shortages FDA Confirms Lilly’s GLP-1s Are Not in Shortage, Gives Compounders Grace Period ...
thereby extending life for the masses, and more importantly, extending quality of life. The number of clinical trials of therapeutics designed to interrupt the process that leads to cancer and cardiovascular
Albuked Solution 10 g/50mL Intravenous Kedrion Biopharma, Inc. 1981-07-28 2017-04-29 Albumin (Human) Solution 200 g/1000mL Intravenous Octapharma Pharmazeutika Produktionsgesellschaft M.B.H. 2006-10-17 Not applicable Albumin (Human) Solution 250 g/1000mL Intravenous Octapharma Italy S.P.A...
SOURCE Kira Pharmaceuticals EventsAsia MORE ON THIS TOPIC Layoffs The 5 Largest Biopharma Layoffs of 2024 December 19, 2024 · 7 min read · Angela Gabriel Sickle cell disease Vertex, Beam Report SCD Cell and Gene Therapies Advance...
A.S. is the recipient of research grants from Roche-Genentech, Abbvie, GSK, Scipher Medicine, Pfizer, Alimentiv, Inc, Boehringer Ingelheim and Agomab; receives consulting fees from Genentech, GSK, Pfizer, HotSpot Therapeutics, Alimentiv, Origo Biopharma, Deep Track Capital, Great Point Partners...
WhitepaperTrend Report: The Nexus Between Patient and Big Pharma Collaborations between contract development and manufacturing organisations (CDMOs) and contract research organisations (CRO) are on the rise. With complex therapeutics in the pipeline and the need for supply chain resiliency, these collabo...
Albuminum Biopharma Biopharma, Georgia Albunate CSL Behring, Mexico Albunorm Octapharma, Bulgaria; Octapharma, Bulgaria; Octapharma, Bulgaria; Octapharma, Czech Republic; Octapharma, Estonia; Octapharma, Spain; Octapharma, Finland; Octapharma, Georgia; Octapharma, Italy; Octapharma, Lithuania; Octapharma, ...
Leo Pharma, Novan, Novartis, Pfizer, Ralexar, Regeneron Pharmaceuticals, Sienna Biopharma, UCB, and UNION Therapeutics/Antibiotx; and is a consultant for AbbVie, Aditum Bio, Almirall, Alpine, Amgen, Arena, Asana Biosciences, AstraZeneca, Bluefin Biomedicine, Boehringer Ingelheim, Boston Pharmaceutic...
Vivodyne today announced the close of $38 million in total seed financing, led by Khosla Ventures, with participation from Kairos Ventures, CS Ventures, MBX Capital, and Bison Ventures.
NurrOn Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing novel, targeted therapeutics for the treatment of Parkinson's disease (PD) and other Nurr1-related incurable human disorders. Through targeting Nurr1, the ...